BDBM50221566 4-chloro-3-(5-methyl-3-(4-(2-(pyrrolidin-1-yl)ethoxy)phenylamino)benzo[e][1,2,4]triazin-7-yl)phenol::4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenol::CHEMBL400402::US8481536, 449::US8481536, 597

SMILES Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl

InChI Key InChIKey=AQSSMEORRLJZLU-UHFFFAOYSA-N

Data  2 KI  7 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 9 hits for monomerid = 50221566   

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Targegen

Curated by ChEMBL
LigandPNGBDBM50221566(4-chloro-3-(5-methyl-3-(4-(2-(pyrrolidin-1-yl)etho...)
Affinity DataKi:  1.30nMAssay Description:Inhibition of SrcMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetTyrosine-protein kinase ABL1(Human)
Targegen

Curated by ChEMBL
LigandPNGBDBM50221566(4-chloro-3-(5-methyl-3-(4-(2-(pyrrolidin-1-yl)etho...)
Affinity DataKi:  1.30nMAssay Description:Inhibition of AblMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetPlatelet-derived growth factor receptor beta(Human)
Targegen

US Patent
LigandPNGBDBM50221566(4-chloro-3-(5-methyl-3-(4-(2-(pyrrolidin-1-yl)etho...)
Affinity DataIC50:  1.10nMAssay Description:Testing of inhibition of kinases in vitro using luciferase-based assay from KinaseGlo, Promega Corp.More data for this Ligand-Target Pair
In DepthDetails US Patent


TargetEphrin type-B receptor 4(Human)
Targegen

US Patent
LigandPNGBDBM50221566(4-chloro-3-(5-methyl-3-(4-(2-(pyrrolidin-1-yl)etho...)
Affinity DataIC50:  15.9nMT: 37°CAssay Description:Testing of inhibition of kinases in vitro using luciferase-based assay from KinaseGlo, Promega Corp.More data for this Ligand-Target Pair
In DepthDetails US Patent


TargetProto-oncogene tyrosine-protein kinase Src(Human)
Targegen

Curated by ChEMBL
LigandPNGBDBM50221566(4-chloro-3-(5-methyl-3-(4-(2-(pyrrolidin-1-yl)etho...)
Affinity DataIC50:  1.80nMAssay Description:Inhibition of SrcMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetTyrosine-protein kinase Yes(Human)
Targegen

Curated by ChEMBL
LigandPNGBDBM50221566(4-chloro-3-(5-methyl-3-(4-(2-(pyrrolidin-1-yl)etho...)
Affinity DataIC50:  0.300nMAssay Description:Inhibition of YESMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

LigandPNGBDBM50221566(4-chloro-3-(5-methyl-3-(4-(2-(pyrrolidin-1-yl)etho...)
Affinity DataIC50:  2.20nMAssay Description:Inhibition of VEGFR2More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetTyrosine-protein kinase Yes(Human)
Targegen

Curated by ChEMBL
LigandPNGBDBM50221566(4-chloro-3-(5-methyl-3-(4-(2-(pyrrolidin-1-yl)etho...)
Affinity DataIC50:  0.5nMT: 25°CAssay Description:Testing of inhibition of kinases in vitro using luciferase-based assay from KinaseGlo, Promega Corp.More data for this Ligand-Target Pair
In DepthDetails US Patent


TargetProto-oncogene tyrosine-protein kinase Src(Human)
Targegen

Curated by ChEMBL
LigandPNGBDBM50221566(4-chloro-3-(5-methyl-3-(4-(2-(pyrrolidin-1-yl)etho...)
Affinity DataIC50:  1.60nMT: 25°CAssay Description:Testing of inhibition of kinases in vitro using luciferase-based assay from KinaseGlo, Promega Corp.More data for this Ligand-Target Pair
In DepthDetails US Patent